(GMED) Globus Medical - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 11.513m USD | Total Return: 42.8% in 12m
Avg Turnover: 135M
EPS Trend: 98.1%
Qual. Beats: 4
Rev. Trend: 93.0%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Confidence
Globus Medical (NYSE: GMED) is a medical device manufacturer specializing in musculoskeletal solutions, including spinal implants, orthopedic trauma hardware, and joint reconstruction systems. The company operates within the high-barrier-to-entry orthopedic sector, where growth is increasingly driven by the integration of robotic-assisted surgery and digital navigation platforms. Its product ecosystem spans traditional fusion implants, motion preservation technologies, and interventional solutions for vertebral compression fractures.
The business model leverages a hybrid sales force of direct representatives and independent distributors to market hardware alongside advanced surgical robotics, such as the ExcelsiusGPS and ExcelsiusFlex platforms. These robotic systems function as razor-and-blade drivers, where the initial capital equipment placement secures long-term utilization of proprietary consumables and implants. Additionally, the company provides neuromonitoring and spinal cord stimulation services to support comprehensive intraoperative and post-operative care.
Evaluating how these technological advancements impact long-term valuation on ValueRay can provide deeper insight into the companys competitive positioning. Headquartered in Pennsylvania, Globus Medical continues to expand its footprint in both domestic and international markets through a focus on minimally invasive procedural innovation.
- NuVasive merger integration synergies drive long-term operating margin expansion
- Robotic navigation platform adoption accelerates pull-through for high-margin spinal implants
- Expansion into orthopedic trauma and total knee markets diversifies revenue streams
- Competitive pricing pressures in domestic spine markets impact core product profitability
- Global supply chain stability influences manufacturing costs for medical grade titanium implants
| Net Income: 586.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: 55.33% < 20% (prev 52.79%; Δ 2.54% < -1%) |
| CFO/TA 0.14 > 3% & CFO 778.5m > Net Income 586.7m |
| Net Debt (-514.6m) to EBITDA (886.4m): -0.58 < 3 |
| Current Ratio: 4.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago -1.13% < -2% |
| Gross Margin: 67.86% > 18% (prev 0.61%; Δ 6.73k% > 0.5%) |
| Asset Turnover: 61.09% > 50% (prev 53.30%; Δ 7.80% > 0%) |
| Interest Coverage Ratio: 79.72 > 6 (EBITDA TTM 886.4m / Interest Expense TTM 7.58m) |
| A: 0.32 (Total Current Assets 2.20b - Total Current Liabilities 482.5m) / Total Assets 5.44b |
| B: 0.28 (Retained Earnings 1.51b / Total Assets 5.44b) |
| C: 0.12 (EBIT TTM 604.4m / Avg Total Assets 5.08b) |
| D: 2.16 (Book Value of Equity 1.53b / Total Liabilities 707.2m) |
| Altman-Z'' = 6.04 = AAA |
| DSRI: 1.03 (Receivables 686.4m/538.1m, Revenue 3.10b/2.51b) |
| GMI: 0.89 (GM 67.86% / 60.59%) |
| AQI: 0.95 (AQ_t 0.48 / AQ_t-1 0.51) |
| SGI: 1.23 (Revenue 3.10b / 2.51b) |
| TATA: -0.04 (NI 586.7m - CFO 778.5m) / TA 5.44b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 85.10 with a total of 1,877,015 shares traded.
Over the past week, the price has changed by +7.82%,
over one month by -9.18%,
over three months by -12.00% and
over the past year by +42.81%.
Globus Medical has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy GMED.
- StrongBuy: 4
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 111.1 | 30.5% |
P/E Trailing = 19.8154
P/E Forward = 18.6916
P/S = 3.7129
P/B = 2.4327
P/EG = 1.7253
Revenue TTM = 3.10b USD
EBIT TTM = 604.4m USD
EBITDA TTM = 886.4m USD
Long Term Debt = 100.1m USD (estimated: total debt 115.2m - short term 15.1m)
Short Term Debt = 15.1m USD (from shortTermDebt, last quarter)
Debt = 115.2m USD (from shortLongTermDebtTotal, last quarter) (leases 115.2m already included)
Net Debt = -514.6m USD (calculated: Debt 115.2m - CCE 629.9m)
Enterprise Value = 11.0b USD (11.5b + Debt 115.2m - CCE 629.9m)
Interest Coverage Ratio = 79.72 (Ebit TTM 604.4m / Interest Expense TTM 7.58m)
EV/FCF = 18.17x (Enterprise Value 11.0b / FCF TTM 605.3m)
FCF Yield = 5.50% (FCF TTM 605.3m / Enterprise Value 11.0b)
FCF Margin = 19.52% (FCF TTM 605.3m / Revenue TTM 3.10b)
Net Margin = 18.92% (Net Income TTM 586.7m / Revenue TTM 3.10b)
Gross Margin = 67.86% ((Revenue TTM 3.10b - Cost of Revenue TTM 996.5m) / Revenue TTM)
Gross Margin QoQ = 69.20% (prev 72.02%)
Tobins Q-Ratio = 2.02 (Enterprise Value 11.0b / Total Assets 5.44b)
Interest Expense / Debt = 6.58% (Interest Expense 7.58m / Debt 115.2m)
Taxrate = 20.86% (32.8m / 157.1m)
NOPAT = 478.3m (EBIT 604.4m * (1 - 20.86%))
Current Ratio = 4.56 (Total Current Assets 2.20b / Total Current Liabilities 482.5m)
Debt / Equity = 0.02 (Debt 115.2m / totalStockholderEquity, last quarter 4.73b)
Debt / EBITDA = -0.58 (Net Debt -514.6m / EBITDA 886.4m)
Debt / FCF = -0.85 (Net Debt -514.6m / FCF TTM 605.3m)
Total Stockholder Equity = 4.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.56% (Net Income 586.7m / Total Assets 5.44b)
RoE = 13.04% (Net Income TTM 586.7m / Total Stockholder Equity 4.50b)
RoCE = 13.14% (EBIT 604.4m / Capital Employed (Equity 4.50b + L.T.Debt 100.1m))
RoIC = 9.98% (NOPAT 478.3m / Invested Capital 4.79b)
WACC = 8.00% (E(11.5b)/V(11.6b) * Re(8.03%) + D(115.2m)/V(11.6b) * Rd(6.58%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.00 | Cagr: 8.44%
[DCF] Terminal Value 77.97% ; FCFF base≈570.2m ; Y1≈653.7m ; Y5≈962.0m
[DCF] Fair Price = 132.3 (EV 14.5b - Net Debt -514.6m = Equity 15.0b / Shares 113.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.08 | EPS CAGR: 27.05% | SUE: 1.51 | # QB: 4
Revenue Correlation: 93.01 | Revenue CAGR: 42.38% | SUE: 0.98 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=+3.74% | Revisions=+60% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.16 | Chg30d=-0.22% | Revisions=+20% | Analysts=14
EPS current Year (2026-12-31): EPS=4.72 | Chg30d=+5.67% | Revisions=+73% | GrowthEPS=+18.7% | GrowthRev=+9.0%
EPS next Year (2027-12-31): EPS=5.14 | Chg30d=+3.76% | Revisions=+73% | GrowthEPS=+8.8% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +73%